Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9UBX5: Variant p.Arg373Cys

Fibulin-5
Gene: FBLN5
Feedback?
Variant information Variant position: help 373 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Cysteine (C) at position 373 (R373C, p.Arg373Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In CMT1H. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 373 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 448 The length of the canonical sequence.
Location on the sequence: help MDVVSGRSVPADIFQMQATT R YPGAYYIFQIKSGNEGREFY The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         MDVVSGRSVPADIFQMQATTRYPGAYYIFQIKSGNEGREFY

Mouse                         MDVVSGRSVPADIFQMQATTRYPGAYYIFQIKSGNEGREFY

Rat                           MDVVSGRSVPADIFQMQATTRYPGAYYIFQIKSGNEGREFY

Bovine                        MDVVSGRSVPADIFQMQATTRYPGAYYIFQIKSGNDGREFY

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 24 – 448 Fibulin-5
Region 245 – 448 Interaction with LOXL1



Literature citations
Fibulin-5 mutations link inherited neuropathies, age-related macular degeneration and hyperelastic skin.
Auer-Grumbach M.; Weger M.; Fink-Puches R.; Papic L.; Froehlich E.; Auer-Grumbach P.; El Shabrawi-Caelen L.; Schabhuettl M.; Windpassinger C.; Senderek J.; Budka H.; Trajanoski S.; Janecke A.R.; Haas A.; Metze D.; Pieber T.R.; Guelly C.;
Brain 134:1839-1852(2011)
Cited for: VARIANTS CMT1H ILE-48; SER-90; SER-267 AND CYS-373; VARIANT MET-126; Czech family confirms the link between FBLN5 and Charcot-Marie-Tooth type 1 neuropathy.
Safka Brozkova D.; Lassuthova P.; Neupauerova J.; Krutova M.; Haberlova J.; Stejskal D.; Seeman P.;
Brain 136:E232-E232(2013)
Cited for: VARIANT CMT1H CYS-373;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.